CONRAY 325

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CONRAY 325 (CONRAY 325).

How it works

Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.

What the body does with it

Metabolism	Not metabolized; excreted unchanged by glomerular filtration.
Excretion	Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Half-life	Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Protein binding	Negligible protein binding (<5%); primarily binds to albumin.
Volume of Distribution	Approximately 0.3 L/kg (total body water); indicates distribution primarily in extracellular fluid.
Bioavailability	Not applicable for oral route (0% bioavailability). Administered only intravascularly; 100% bioavailability following IV administration.
Onset of Action	Intravenous: immediate (within seconds to minutes). Intra-arterial: immediate. Oral: not applicable (no oral absorption).
Duration of Action	Rapid redistribution and renal elimination result in a short duration of contrast enhancement (minutes). Clinically, adequate opacification typically lasts 10-30 minutes after bolus injection.

Classification & Brands

Dosing & administration

Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.

Dosage form	INJECTABLE
Renal impairment	eGFR <30 mL/min/1.73 m²: use with caution, consider alternative imaging; no established dose reduction. eGFR 30-59: ensure adequate hydration; no dose adjustment required.
Liver impairment	No specific dose adjustment for Child-Pugh class; use standard dosing with monitoring for adverse effects.
Pediatric use	Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum 125 mL total.
Geriatric use	No specific dose adjustment; assess renal function (eGFR) and hydration status prior to administration.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CONRAY 325 (CONRAY 325).

Breastfeeding	IO contrast agents excreted in breast milk in very small amounts (M/P ratio unknown, likely <1%). For iothalamate, estimated relative infant dose <0.1% of maternal dose. Consider temporary cessation of breastfeeding for 12-24 hours post-administration.
Teratogenic Risk	IONP: Category B. No evidence of teratogenicity in animal studies; limited human data. Radiopaque contrast agents cross placenta transiently. Theoretical risk of neonatal hypothyroidism exists but not confirmed with iothalamate meglumine.

Warnings & precautions

■ FDA Black Box Warning

Risk of serious hypersensitivity reactions and severe contrast media reactions, including fatal anaphylaxis. Patients with a history of reaction to contrast media, asthma, or allergies are at increased risk.

Side Effect Profile

Serious Effects

Absolute Contraindications

Known hypersensitivity to iothalamate meglumine or any component, anuria, and concomitant administration of corticosteroids (risk of increased toxicity).

Clinical Precautions

Precautions

Acute kidney injury (especially in patients with pre-existing renal impairment, diabetes, dehydration), hypersensitivity reactions, thyroid dysfunction (in patients with hyperthyroidism or thyroid tumors), and CNS effects (seizures, confusion).

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CONRAY 325

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CONRAY 325 (CONRAY 325).

How it works

Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.

What the body does with it

Metabolism	Not metabolized; excreted unchanged by glomerular filtration.
Excretion	Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Half-life	Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Protein binding	Negligible protein binding (<5%); primarily binds to albumin.
Volume of Distribution	Approximately 0.3 L/kg (total body water); indicates distribution primarily in extracellular fluid.
Bioavailability	Not applicable for oral route (0% bioavailability). Administered only intravascularly; 100% bioavailability following IV administration.
Onset of Action	Intravenous: immediate (within seconds to minutes). Intra-arterial: immediate. Oral: not applicable (no oral absorption).
Duration of Action	Rapid redistribution and renal elimination result in a short duration of contrast enhancement (minutes). Clinically, adequate opacification typically lasts 10-30 minutes after bolus injection.

Classification & Brands

Dosing & administration

Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.

Dosage form	INJECTABLE
Renal impairment	eGFR <30 mL/min/1.73 m²: use with caution, consider alternative imaging; no established dose reduction. eGFR 30-59: ensure adequate hydration; no dose adjustment required.
Liver impairment	No specific dose adjustment for Child-Pugh class; use standard dosing with monitoring for adverse effects.
Pediatric use	Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum 125 mL total.
Geriatric use	No specific dose adjustment; assess renal function (eGFR) and hydration status prior to administration.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CONRAY 325 (CONRAY 325).

Breastfeeding	IO contrast agents excreted in breast milk in very small amounts (M/P ratio unknown, likely <1%). For iothalamate, estimated relative infant dose <0.1% of maternal dose. Consider temporary cessation of breastfeeding for 12-24 hours post-administration.
Teratogenic Risk	IONP: Category B. No evidence of teratogenicity in animal studies; limited human data. Radiopaque contrast agents cross placenta transiently. Theoretical risk of neonatal hypothyroidism exists but not confirmed with iothalamate meglumine.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

Known hypersensitivity to iothalamate meglumine or any component, anuria, and concomitant administration of corticosteroids (risk of increased toxicity).